Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous neoantigen-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Changhai Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
YS247 is an autologous neoantigen-pulsed dendritic cell vaccine being developed by Changhai Hospital for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This personalized immunotherapy involves isolating a patient's peripheral blood mononuclear cells (PBMCs) and differentiating them into dendritic cells (DCs) ex vivo using GM-CSF and IL-4. These DCs are then pulsed with synthetic neoantigen peptides, which are identified through next-generation sequencing (NGS) of the patient's specific tumor tissue to capture unique mutations. Following maturation with a cytokine cocktail (TNF-α, IFN-γ, and PGE2), the vaccine is administered subcutaneously. The goal is to leverage the matured DCs to present these neoantigens to the patient's T cells, thereby inducing a targeted and robust anti-tumor immune response.
- Other names
- Neo-DC
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on autologous neoantigen-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous neoantigen-pulsed dendritic cell vaccine.